摘要
In recent years,the histone methyltransferase SET domain containing 2(SETD2)has garnered significant attention for its involvement in carcinogenesis.Herein we aim to summarize the research advances regarding SETD2 in tumors,elucidate the role in global epigenetic regulation,highlight potential therapeutic regimens for patients with SETD2 deficiency,and outline future research directions.
基金
This work was supported by the National Natural Science Foundation of China(Grant Nos.82073105 and 32370833)
the State Key Laboratory of Systems Medicine for Cancer(Grant No.KF2412).
